KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

本项首次人体（FIH）剂量爬坡与剂量验证/扩展队列研究，将评估法尼基转移酶抑制剂（FTI）KO-2806作为单药疗法与联合疗法，在晚期实体瘤成人患者中的应用效果。